Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification.
about
Acetylcysteine for preventing contrast-induced nephropathyAcetylcysteine for preventing contrast-induced nephropathyRenal Safety of Iodinated Contrast Media Depending on Their Osmolarity - Current OutlooksRisk prediction models for contrast induced nephropathy: systematic reviewContrast Medium-Induced Acute Kidney InjuryRadiographic contrast-media-induced acute kidney injury: pathophysiology and prophylactic strategiesRisks and complications of coronary angiography: a comprehensive reviewA Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney InjuryAcute kidney injury following peripheral angiography and endovascular therapy: A systematic review of the literature.Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI RegistryPeriprocedural hemoglobin drop and contrast-induced nephropathy in percutaneous coronary intervention patients.Impact of the interval between coronary angiography and off-pump coronary bypass surgery on postoperative renal function.Temporal trends of fluoroscopy time and contrast utilization in coronary chronic total occlusion revascularization: insights from a multicenter United States registry.Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registryMechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol.Contrast-induced nephropathy in patients undergoing percutaneous coronary interventionCompound danshen dripping pill pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Contrast-associated AKI and use of cardiovascular medications after acute coronary syndrome.Magnolin protects against contrast-induced nephropathy in rats via antioxidation and antiapoptosis.Risk scoring system to predict contrast induced nephropathy following percutaneous coronary intervention.The current state of endovascular therapy in the evaluation and management of renovascular disease.Cardiological Society of India practice guidelines for angiography in patients with renal dysfunction.N-acetylcysteine does not prevent contrast nephropathy in patients with renal impairment undergoing emergency CT: a randomized study.Diastolic dysfunction is associated with an increased risk of contrast-induced nephropathy: a retrospective cohort studyDetermination of safe contrast media dosage to estimated glomerular filtration rate ratios to avoid contrast-induced nephropathy after elective percutaneous coronary intervention.Clinical prediction scores for type 1 cardiorenal syndrome derived and validated in chinese cohorts.Update of acute kidney injury: intensive care nephrology.Contrast-induced acute kidney injury: short- and long-term implications.Contrast-induced nephropathy in interventional cardiologyRosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction.Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback.Association between Platelet-to-Lymphocyte Ratio and Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome.Efficacy of Short-Term Statin Treatment for the Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention: A Meta-Analysis of 21 Randomized Controlled Trials.Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography.Preprocedural N-terminal pro-brain natriuretic peptide (NT-proBNP) is similar to the Mehran contrast-induced nephropathy (CIN) score in predicting CIN following elective coronary angiography.Remote Ischemic Preconditioning for the Prevention of Contrast-Induced Acute Kidney Injury in Diabetics Receiving Elective Percutaneous Coronary InterventionComparison of the efficacy of recombinant human brain natriuretic peptide with saline hydration in preventing contrast-induced nephropathy in patients undergoing coronary angiography with or without concomitant percutaneous coronary interventionImpact of biplane versus single-plane imaging on radiation dose, contrast load and procedural time in coronary angioplastySerum hyperchloremia as a risk factor for acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention
P2860
Q24187683-CE0D9495-2425-4203-BAA9-6575E9BC2FEBQ24194049-0775063E-0341-4BB9-BE30-B6A34507D603Q26747754-6735F2DB-A096-4B7E-8AFE-D001218D45EFQ26796473-1C39DE7E-905D-4EA0-953D-58E57BC0C1CFQ26801447-35231906-DA11-41DA-967A-2CA82CDE66F2Q27021421-3B802D8C-FB76-48D3-854A-B17206B38F9EQ27025085-9FB58C87-5543-42C7-8DB2-1A7A672BB7F0Q28082619-0B087EA0-0D5C-49B7-AAD0-4847BE4565D3Q30251827-D872CCC2-B92A-444C-B013-9F9892A09452Q30878953-98465A3F-B3FF-4449-85F3-2C63EB11FA1BQ33685017-64983FF8-558F-4CCB-89EF-19F9C0CF8453Q33861539-4DA568AC-16D6-4E3B-99A1-F6492CD790FBQ33875729-67BC6096-59FE-4A12-BF7B-092D8FE83B51Q34005294-EF3FDEB1-0344-4698-B41B-275C99A389F8Q34150613-9BA911C2-4347-441F-A155-4A0DD49A9122Q34155673-4AC05FF0-7219-4660-A1F8-A823F294D5D2Q34438015-F8E6B28D-E79E-495D-B1B4-7D92DCD660F6Q34455207-54089ADB-D104-4319-A749-2C147E808D29Q34460965-0CB826B6-10D3-4BF6-B1CD-7BB6A6270A15Q34467009-9FAA6E65-497F-44D0-B0AB-D15FFED3F9B8Q34563720-31F61424-00E4-411B-9149-73CCC8B84BDAQ34574872-B25462CF-6D15-4566-BAD5-3495526D65A0Q34753666-5C29939E-A2D0-4477-919B-DBE7DF0FE58BQ34816125-3A369D1D-979C-43D8-95DC-BB852913A033Q35048384-15C97ED9-8352-47C3-A79B-652ACFE2CD50Q35081524-B7EDC95B-D224-4872-847D-8A627AD65648Q35115570-E6D81723-9CC0-42B6-A905-98B5D85C0585Q35127308-36282E7D-BF8E-4903-AF14-57576E26CBB8Q35193141-BF71C4C2-72AC-4297-9FCC-D087B4E11303Q35480312-25ED298A-A997-4115-BF45-C5B0F40A9A43Q35567713-307DA10C-C12A-4A2E-AC86-8F6F3FC088B1Q35576454-2705C35E-659E-4FEF-A4B2-F0DF46FFA6CFQ35592454-7AEFCEEA-8E74-4882-A3B4-27D3D139F905Q35930002-3C98EB70-EAFA-46A2-9611-6933435962D6Q35999430-B4AAF96D-6261-45EC-89A5-789FAB5F417FQ36085790-E10E8A62-3135-4BEB-AE40-3A435FFB2575Q36159523-3F639419-4AE7-44FE-A0AE-DB3BB0174A5FQ36183555-52D2C75A-4D36-4668-A584-79BD4C3A82F0Q36324396-9EAD4549-0E2D-4597-9524-3D36BF04A18BQ36368496-A66634E8-2D9C-4D11-8DB8-ECB115183FC3
P2860
Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Impact of nephropathy after pe ...... ethod for risk stratification.
@en
Impact of nephropathy after pe ...... ethod for risk stratification.
@nl
type
label
Impact of nephropathy after pe ...... ethod for risk stratification.
@en
Impact of nephropathy after pe ...... ethod for risk stratification.
@nl
prefLabel
Impact of nephropathy after pe ...... ethod for risk stratification.
@en
Impact of nephropathy after pe ...... ethod for risk stratification.
@nl
P2093
P1476
Impact of nephropathy after pe ...... ethod for risk stratification.
@en
P2093
Beth A Bartholomew
Cindy L Grines
Judith A Boura
Kishore J Harjai
Michael W Yerkey
Srinivas Dukkipati
Susan Glazier
William W O'Neill
P304
P356
10.1016/J.AMJCARD.2004.03.008
P407
P577
2004-06-01T00:00:00Z